Fermented mistletoe extract as a multimodal antitumoral agent in gliomas

Evidence-based Complementary and Alternative Medicine

Volumn 2012, Issue , 2012, Pages

  Podlech, Oliver ^a   Harter, Patrick N ^b   Mittelbronn, Michel ^b   Pöschel, Simone ^a   Naumann, Ulrike ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE A; GELATINASE B; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR NKG2D; PLANT EXTRACT; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VISCUM ALBUM LECTIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELLULAR IMMUNITY; COCULTURE; CONTROLLED STUDY; CYTOLYSIS; DOWN REGULATION; ENZYME ACTIVITY; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT; VISCUM ALBUM;

EID: 84868674672     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2012/501796     Document Type: Article

References (58)

1. Stupp R., Mason W. P., Van Den Bent M. J., Weller M., Fisher B., Taphoorn M. J. B., Belanger K., Brandes A. A., Marosi C., Bogdahn U., Curschmann J., Janzer R. C., Ludwin S. K., Gorlia T., Allgeier A., Lacombe D., Cairncross J. G., Eisenhauer E., Mirimanoff R. O., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 2005 352 10 987 996 2-s2.0-20044366163 10.1056/NEJMoa043330 (Pubitemid 40349501)
2. Hermisson M., Klumpp A., Wick W., Wischhusen J., Nagel G., Roos W., Kaina B., Weller M., O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. Journal of Neurochemistry 2006 96 3 766 776 2-s2.0-33645105856 10.1111/j.1471-4159.2005. 03583.x
3. Weller M., Rieger J., Grimmel C., Van Meir E. G., De Tribolet N., Krajewski S., Reed J. C., von Deimling A., Dichgans J., Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. International Journal of Cancer 1998 79 6 640 644 (Pubitemid 28549478)
4. Weller M., Fontana A., The failure of current immunotherapy for malignant glioma. Tumor-derived TGF- β T-cell apoptosis, and the immune privilege of the brain. Brain Research Reviews 1995 21 2 128 151 2-s2.0-0029610610 10.1016/0165-0173(95)00010-0 (Pubitemid 26060933)
5. Platten M., Wick W., Weller M M., Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microscopic Research Technology 2001 52 4 401 410 (Pubitemid 32167828)
6. Nikolai G., Friedl P., Werner M., Niggemann B., Zänker K. S., Effect of a mistletoe extract (Iscador® QuFrF) on viability and migratory behavior of human peripheral CD4+ and CD8+ T lymphocytes in three-dimensional collagen lattices. In Vitro Cellular and Developmental Biology 1997 33 9 710 716 2-s2.0-0030660248 (Pubitemid 27488458)
7. Gren A., Effects of Iscador preparations on the reactivity of mouse immune system. Neuroendocrinology Letters 2009 30 4 530 534 2-s2.0-76049124256
8. Lee C. H., Kim J. K., Kim H. Y., Park S. M., Lee S. M., Immunomodulating effects of Korean mistletoe lectin in vitro and in vivo. International Immunopharmacology 2009 9 13-14 1555 1561 2-s2.0-70350564317 10.1016/j.intimp.2009.09.011
9. Braedel-Ruoff S., Immunomodulatory effects of Viscum album extracts on natural killer cells: review of clinical trials. Forschende Komplementarmedizin 2010 17 2 63 73 2-s2.0-77952920116 10.1159/000288702
10. Stein G. M., Büssing A., Schietzel M., Stimulation of the maturation of dendritic cells in vitro by a fermented mistletoe extract. Anticancer Research 2002 22 6 4215 4219 2-s2.0-0036875802 (Pubitemid 36134460)
11. Hajtó T., Fodor K., Perjési P., Németh P., Difficulties and perspectives of immunomodulatory therapy with mistletoe lectins and standardized mistletoe extracts in evidence-based medicine. Evidence-Based Complementary and Alternative Medicine 2011 2011 6 2-s2.0-79952229138 10.1093/ecam/nep191 298972
12. Gardin N. E., Immunological response to mistletoe (Viscum album L.) in cancer patients: a four-case series. Phytotherapy Research 2009 23 3 407 411 2-s2.0-61449189674 10.1002/ptr.2643
13. Park H. J., Hong J. H., Kwon H. J., Kim Y., Lee K. H., Kim J. B., Song S. K., TLR4-mediated activation of mouse macrophages by Korean mistletoe lectin-C (KML-C). Biochemical and Biophysical Research Communications 2010 396 3 721 725 2-s2.0-77953022880 10.1016/j.bbrc.2010.04.169
14. Stirpe F., Sandvig K., Olsnes S., Pihl A., Action of viscumin, a toxic lectin from mistletoe, on cells in culture. Journal of Biological Chemistry 1982 257 22 13271 13277 2-s2.0-0020405898 (Pubitemid 13188941)
15. Büssing A., Schietzel M., Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. Anticancer Research 1999 19 1 23 28 2-s2.0-0344628679 (Pubitemid 29168216)
16. Büssing A., Suzart K., Schweizer K., Differences in the apoptosis-inducing properties of Viscum album L. extracts. Anti-Cancer Drugs 1997 8 1, supplement S9 S14 2-s2.0-0030957045 (Pubitemid 27202383)
17. Burger A. M., Mengs U., Schüler J. B., Fiebig H. H., Antiproliferative activity of an aqueous mistletoe extract in human tumor cell lines and xenografts in vitro. Arzneimittel-Forschung 2001 51 9 748 757 2-s2.0-0034837768 (Pubitemid 32889398)
18. Park W. B., Lyu S. Y., Kim J. H., Choi S. H., Chung H. K., Ahn S. H., Hong S. Y., Yoon T. J., Choi M. J., Inhibition of tumor growth and metastasis by Korean mistletoe lectin is associated with apoptosis and antiangiogenesis. Cancer Biotherapy and Radiopharmaceuticals 2001 16 5 439 447 2-s2.0-0035216950
19. Choi S. H., Lyu S. Y., Park W. B., Mistletoe lectin induces apoptosis and telomerase inhibition in human A253 cancer cells through dephosphorylation of Akt. Archives of Pharmacal Research 2004 27 1 68 76 2-s2.0-4344613440 (Pubitemid 43154544)
20. Lyu S. Y., Park W. B., Choi K. H., Kim W. H., Involvement of caspase-3 in apoptosis induced by Viscum album var. coloratum agglutinin in HL-60 cells. Bioscience, Biotechnology and Biochemistry 2001 65 3 534 541 2-s2.0-0035293795 10.1271/bbb.65.534 (Pubitemid 33615916)
21. Lyu S. Y., Park W. B., Mistletoe lectin (Viscum album coloratum) modulates proliferation and cytokine expressions in murine splenocytes. Journal of Biochemistry and Molecular Biology 2006 39 6 662 670 2-s2.0-33845402340
22. Thies A., Dautel P., Meyer A., Pfüller U., Schumacher U., Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model. British Journal of Cancer 2008 98 1 106 112 2-s2.0-38049015487 10.1038/sj.bjc.6604106
23. Beuth J., Ko H. L., Schneider H., Tawadros S., Kasper H. U., Zimst H., Schierholz J. M., Intratumoral application of standardized mistletoe extracts down regulates tumor weight via decreased cell proliferation, increased apoptosis and necrosis in a murine model. Anticancer Research 2006 26 6 4451 4456 2-s2.0-33845955943 (Pubitemid 46031521)
24. Pryme I. F., Bardocz S., Pusztai A., Ewen S. W. B., Suppression of growth of tumour cell lines in vitro and tumours in vivo by mistletoe lectins. Histology and Histopathology 2006 21 13 285 299 2-s2.0-29844438773 (Pubitemid 43033738)
25. Burger A. M., Mengs U., Schüler J. B., Fiebig H. H., Anticancer activity of an aqueous mistletoe extract (AME) in syngeneic murine tumor models. Anticancer Research 2001 21 3 1965 1968 2-s2.0-0034909467 (Pubitemid 32728937)
26. Lenartz D., Andermahr J., Plum G., Menzel J., Beuth J., Efficiency of treatment with galactoside-specific lectin from mistletoe against rat glioma. Anticancer Research 1998 18 2 1011 1014 2-s2.0-0031840920 (Pubitemid 28239631)
27. Büssing A., Raak C., Ostermann T., Quality of life and related dimensions in cancer patients treated with mistletoe extract (Iscador): a meta-analysis. Evidence Based Complementary and Alternative Medicine 2012 2012 8 10.1155/2012/219402 219402
28. Matthes H., Friedel W. E., Bock P. R., Zänker K. S., Molecular mistletoe therapy: friend or foe in established antitumor protocols? a multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer. Current Molecular Medicine 2010 10 4 430 439 2-s2.0-77953523650 10.2174/156652410791317057
29. Kienle G. S., Kiene H., Influence of Viscum album L (European Mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integrative Cancer Therapies 2010 9 2 142 157 2-s2.0-77954199043 10.1177/1534735410369673
30. Ostermann T., Raak C., Büssing A., Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer 2009 9, article 451 2-s2.0-74249108509 10.1186/1471-2407-9-451
31. Ziegler R., Grossarth-Maticek R., Individual patient data meta-analysis of survival and psychosomatic self-regulation from published prospective controlled cohort studies for long-term therapy of breast cancer patients with a mistletoe preparation (Iscador). Evidence-Based Complementary and Alternative Medicine 2010 7 2 157 166 2-s2.0-77952190319 10.1093/ecam/nen025
32. Lenartz D., Dott U., Menzel J., Schierholz J. M., Beuth J., Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Research 2000 20 3 2073 2076 2-s2.0-0033877281 (Pubitemid 30636185)
33. Friese M. A., Platten M., Lutz S. Z., Naumann U., Aulwurm S., Bischof F., Bühring H. J., Dichgans J., Rammensee H. G., Steinle A., Weller M., MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Research 2003 63 24 8996 9006 2-s2.0-9144273780 (Pubitemid 38064081)
34. Antony S., Kuttan R., Kuttan G., Role of natural killer cells in Iscador mediated inhibition of metastasis by adoptive immunotherapy. Immunological Investigations 2000 29 3 219 231 2-s2.0-0033860751 (Pubitemid 30616489)
35. Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A. C., Van Meir E. G., Frequent co-alterations of TP53, p16/CDKN2A, p14(ARF), PTEN tumor suppressor genes in human glioma cell lines. Brain Pathology 1999 9 3 469 479 2-s2.0-0032977124 (Pubitemid 29316287)
36. Vanmeter T. E., Rooprai H. K., Kibble M. M., Fillmore H. L., Broaddus W. C., Pilkington G. J., The role of matrix metalloproteinase genes in glioma invasion: co-dependent and interactive proteolysis. Journal of Neuro-Oncology 2001 53 2 213 235 2-s2.0-0034753865 10.1023/A:1012280925031 (Pubitemid 33034693)
37. Wick W., Platten M., Weller M., Glioma cell invasion: regulation of metalloproteinase activity by TGF- β Journal of Neuro-Oncology 2001 53 2 177 185 2-s2.0-0034765067 10.1023/A:1012209518843 (Pubitemid 33034690)
38. Pilkington G. J., Darling J. L., Lantos P. L., Thomas D. G. T., Cell lines (VMDk) derived from a spontaneous murine astrocytoma. Morphological and immunocytochemical characterization. Journal of the Neurological Sciences 1983 62 13 115 139 2-s2.0-0021024533 (Pubitemid 14176243)
39. Pilkington G. J., Darling J. L., Lantos P. L., Thomas D. G. T., Tumorigenicity of cell lines (VMDk) derived from a spontaneous murine astrocytoma. Histology, fine structure and immunocytochemistry of tumours. Journal of the Neurological Sciences 1985 71 2-3 145 164 2-s2.0-0022353173 (Pubitemid 16207462)
40. Naumann U., Kügler S., Wolburg H., Wick W., Rascher G., Schulz J. B., Conseiller E., Bähr M., Weller M., Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand. Cancer Research 2001 61 15 5833 5842 2-s2.0-0035422775 (Pubitemid 32769102)
41. Seznec J., Silkenstedt B., Naumann U., Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma. Jorunal of Neurooncology 2011 101 365 377
42. Steinle S. A., Li P., Morris D. L., Groh V., Lanier L. L., Strong R. K., Spies T., Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics 2001 53 4 279 287 (Pubitemid 32678762)
43. Adamopoulou E., Diekmann J., Tolosa E., Kuntz G., Einsele H., Rammensee H. G., Topp M. S., Human CD4+ T cells displaying viral epitopes elicit a functional virus-specific memory CD8+ T cell response. Journal of Immunology 2007 178 9 5465 5472 2-s2.0-34247617743 (Pubitemid 46674340)
44. Koka V., Potti A., Forseen S. E., Pervez H., Fraiman G. N., Koch M., Levitt R., Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme. American Journal of Clinical Oncology 2003 26 4 332 335 2-s2.0-0042564436 10.1097/00000421-200308000-00004 (Pubitemid 36962071)
45. Sasaki T., Lopes M. B. S., Hankins G. R., Helm G. A., Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. Acta Neuropathologica 2002 104 1 105 109 2-s2.0-0036943193 10.1007/s00401-002- 0532-x (Pubitemid 36075365)
46. Georgescu M. M., Pten tumor suppressor network in PI3K-Akt pathway control. Genes and Cancer 2011 1 12 1170 1177 2-s2.0-79960050610 10.1177/1947601911407325
47. Koul D., PTEN signaling pathways in glioblastoma. Cancer Biology and Therapy 2008 7 9 1321 1325 2-s2.0-52149096024
48. Klampfer L., Signal transducers and activators of transcription (STATs): novel targets of chemopreventive and chemotherapeutic drugs. Current Cancer Drug Targets 2006 6 2 107 121 2-s2.0-33645839013 10.2174/156800906776056491
49. Liu C., Sun C., Huang H., Janda K., Edgington T., Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Research 2003 63 11 2957 2964 2-s2.0-0038243036 (Pubitemid 36667169)
50. Bernardo M. M., Fridman R., TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochemical Journal 2003 374 3 739 745 2-s2.0-0141790968 10.1042/BJ20030557 (Pubitemid 37163919)
51. Lu K. V., Jong K. A., Rajasekaran A. K., Cloughesy T. F., Mischel P. S., Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Laboratory Investigation 2004 84 1 8 20 2-s2.0-1542781585 10.1038/sj.labinvest.3700003 (Pubitemid 41656430)
52. Deryugina E. I., Bourdon M. A., Luo G. X., Reisfeld R. A., Strongin A., Matrix metalloproteinase-2 activation modulates glioma cell migration. Journal of Cell Science 1997 110 19 2473 2482 2-s2.0-0001125655 (Pubitemid 127699161)
53. Quo P., Imanishi Y., Cackowski F. C., Jarzynka M. J., Tao H. Q., Nishikawa R., Hirose T., Hu B., Cheng S. Y., Up-regulation of angiopoietin-2, matrix metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 γ 2 correlates with the invasiveness of human glioma. American Journal of Pathology 2005 166 3 877 890 2-s2.0-14644399862 (Pubitemid 40315644)
54. Munaut C., Noël A., Hougrand O., Foidart J. M., Boniver J., Deprez M., Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. International Journal of Cancer 2003 106 6 848 855 2-s2.0-0042839756 10.1002/ijc.11313 (Pubitemid 37071662)
55. Lee O. H., Xu J., Fueyo J., Fuller G. N., Aldape K. D., Alonso M. M., Piao Y., Liu T. J., Lang F. F., Bekele B. N., Gomez-Manzano C., Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin β 1-dependent adhesion to the extracellular matrix. Molecular Cancer Research 2006 4 12 915 926 2-s2.0-33846303242 10.1158/1541-7786.MCR-06- 0184 (Pubitemid 46121550)
56. Kuttan G., Kuttan R., Immunological mechanism of action of the tumor reducing peptide from mistletoe extract (NSC 635089) cellular proliferation. Cancer Letters 1992 66 2 123 130 2-s2.0-0026786948 10.1016/0304-3835(92)90224-J
57. Schink M., Tröger W., Dabidian A., Goyert A., Scheuerecker H., Meyer J., Fischer I. U., Glaser F., Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. A randomized phase III trial. Forschende Komplementarmedizin 2007 14 1 9 17 2-s2.0-33847657527 10.1159/000098135 (Pubitemid 46364562)
58. Li M. O., Wan Y. Y., Sanjabi S., Robertson A. K. L., Flavell R. A., Transforming growth factor- β regulation of immune responses. Annual Review of Immunology 2006 24 99 146 2-s2.0-33646164362 10.1146/annurev.immunol.24. 021605.090737